BIOMARIN PHARMACEUTICAL - EXPECTS $1.55 UNFAVORABLE IMPACT TO GAAP AND NON-GAAP DILUTED EPS FOR FULL YEAR 2026 - SEC FILING

Reuters · 1d ago

Please log in to view news